Changes in Body Composition with Ritonavir‐Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96‐Week Randomized, Controlled Study
| Autor: | Grace A. McComsey, Rong Yang, Victoria Wirtz, Marina Mathew, Donnie McGrath, Anna Rightmire |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Anti-HIV Agents Pyridines Atazanavir Sulfate HIV Infections Gastroenterology law.invention Randomized controlled trial law Antiretroviral Therapy Highly Active Internal medicine Humans Medicine Lipoatrophy Ritonavir Reverse-transcriptase inhibitor business.industry Stavudine virus diseases Lamivudine medicine.disease Virology Atazanavir Infectious Diseases Body Composition HIV-1 Female Lipodystrophy business Oligopeptides medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 48:1323-1326 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1086/597776 |
| Popis: | This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|